首页> 外文OA文献 >Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

【2h】

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

机译：伊马替尼与干扰素和小剂量阿糖胞苷治疗新诊断的慢性期慢性粒细胞白血病的比较

页面导航

著录项
相似文献
相关主题

著录项

作者
OBrien Stephen G; Guilhot François; Larson Richard A; Gathmann Insa; Baccarani Michele; Cervantes Francisco; Cornelissen Jan J; Fischer Thomas; Hochhaus Andreas; Hughes Timothy; Lechner Klaus; Nielsen Johan L; Rousselot Philippe; Reiffers Josy; Saglio Giuseppe; Shepherd John; Simonsson Bengt; Gratwohl Alois; Goldman John M; Kantarjian Hagop; Taylor Kerry; Verhoef Gregor; Bolton Ann E; Capdeville Renaud; Druker Brian J;
展开▼
作者单位

展开▼
年度 2003
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. [J] . OBrien SG, Guilhot F, Larson RA, The New England journal of medicine . 2003,第11期

机译：伊马替尼与干扰素和小剂量阿糖胞苷相比，新诊断出的慢性期慢性粒细胞白血病。
2. Updated Estimates of Survival and Cost Effectiveness for Imatinib versus Interferon-alpha Plus Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukaemia. [J] . Reed SD, Anstrom KJ, Li Y, PharmacoEconomics . 2008,第5期

机译：伊马替尼与干扰素-α加小剂量阿糖胞苷用于新诊断的慢性阶段性骨髓性白血病的生存率和成本效益的最新估计值。
3. Cost-effectiveness study comparing imatinib with interferon-alpha for patients with newly diagnosed chronic-phase (CP) chronic myeloid leukemia (CML) from the Chinese public health-care system perspective (CPHSP). [J] . Chen Z, Wang C, Xu X, Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2009,第Suppla3期

机译：从中国公共卫生保健系统角度（CPHSP）比较伊马替尼与干扰素-α对新诊断的慢性期（CP）慢性髓细胞性白血病（CML）患者的成本效益研究。
4. Combination effects of repetitive pulsed magnetic stimulation and tyrosine kinase inhibitor imatinib for chronic myeloid leukemia cell line TCC-S [C] . S. Yamaguchi, M. Sekino, Y. Sato, Intermag Conference . 2006

机译：重复脉冲磁刺激和酪氨酸激酶抑制剂慢性髓性白血病细胞系TCC-S的组合效应
5. Influences on physician recommendation for imatinib mesylate in chronic phase chronic myeloid leukemia patients. [D] . Iyer, Shrividya Sethuraman. 2003

机译：对慢性期慢性粒细胞白血病患者甲磺酸伊马替尼的医师推荐的影响。
6. Sensitive Detection of Pre-Existing BCR-ABL Kinase Domain Mutations in CD34+ Cells of Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients Is Associated with Imatinib Resistance: Implications in the Post-Imatinib Era [O] . Zafar Iqbal, Aamer Aleem, Mudassar Iqbal, 2010

机译：新诊断的慢性阶段性骨髓性白血病患者CD34 +细胞中先前存在的BCR-ABL激酶结构域突变的敏感检测与伊马替尼耐药相关：在伊马替尼时代后的意义
7. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia [O] . OBrien S., Guilhot F., Larson R., 2003

机译：伊马替尼与干扰素和低剂量阿糖胞苷相比，用于新诊断的慢性期慢性粒细胞白血病

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

著录项

相似文献

相关主题

期刊订阅